▲ NIFTY 50 top gainers HDFCLIFE₹557.00▲ 5.05% TMPV₹314.50▲ 4.49% SBILIFE₹1,766.90▲ 4.06% DRREDDY₹1,175.00▲ 3.07% BEL₹395.45▲ 2.51% INDIGO₹4,845.00▲ 2.36% TATASTEEL₹187.29▲ 2.34% JIOFIN₹229.30▲ 1.98% ETERNAL₹322.35▲ 1.69% SHRIRAMFIN₹995.00▲ 1.63% ▼ NIFTY 50 top losers ONGC₹232.43▼ 1.85% TITAN₹4,841.00▼ 1.38% HDFCBANK₹713.00▼ 1.18% COALINDIA₹418.00▼ 1.01% HINDUNILVR₹1,942.20▼ 1.01% NESTLEIND₹1,370.60▼ 1.00% ICICIBANK₹1,347.60▼ 0.82% BAJAJ-AUTO₹11,500.00▼ 0.80% GRASIM₹3,173.10▼ 0.44% WIPRO₹166.40▼ 0.29% NSE most active PNB₹116.47▼ 0.28% ITC₹266.20▲ 0.78% KOTAKBANK₹416.50▲ 0.36% CANBK₹123.90▲ 0.57%

NSE CIPLA · BSE 500087 · Biotechnology & Drugs · NIFTY 50

Cipla Share Price

Market open · updated 24 Sep, 3:58 PM IST
₹1,405.60 ▲ +₹23.22 · 1.68% NSE · as of 24 Sep 2026, 8:12 AM · BSE ₹1,403.20
Today's range
₹1,367.00Low₹1,418.70High
52-week range
₹1,165.55Low · 2 Apr 2026₹1,672.20High · 23 Oct 2025

Cipla Overview

Where the price stands, how it has moved and how it sits against its averages.

Cipla shares last traded at ₹1,405.60 on the NSE, up 1.68% on the day. That is 15.9% below the 52-week high of ₹1,672.20 and 20.6% above the 52-week low of ₹1,165.55. The stock trades at 35.11× earnings, below the sector average of 36.50. Its market value is ₹1,13,359 Cr.

Price returns

1 Day▲ +1.68%
5 Days▲ +1.84%
This month▼ −1.86%
3 Months▼ −3.82%
6 Months▲ +11.14%
This year▼ −8.49%
1 Year▼ −9.44%

Against the market: 1 Month ▲ +2.08% · 3 Months ▼ −1.04% · 6 Months ▲ +11.80% · This year ▲ +4.22% · 1 Year ▼ −0.63%

Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST).

Moving averages — price is above 4 of 6

  1. 50-day average₹1,423.40 ▼ price 1.3% below
  2. 100-day average₹1,409.46 ▼ price 0.3% below
  3. Today's price₹1,405.60
  4. 20-day average₹1,393.36 ▲ price 0.9% above
  5. 300-day average₹1,387.41 ▲ price 1.3% above
  6. 5-day average₹1,379.80 ▲ price 1.9% above
  7. 10-day average₹1,373.64 ▲ price 2.3% above

Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.

Cipla Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
28,163
Net profit₹ crore · losses below zero
5,273
3,879

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹28,163 Cr ▲ +2.2% ₹3,879 Cr 13.8% ₹48.00 ₹13.00
FY 2025 ₹27,548 Cr ▲ +6.9% ₹5,273 Cr 19.1% ₹65.24 ₹13.00
FY 2024 ₹25,774 Cr ▲ +13.3% ₹4,122 Cr 16.0% ₹51.05 ₹13.00
FY 2023 ₹22,753 Cr ▲ +4.5% ₹2,802 Cr 12.3% ₹34.69 ₹8.50
FY 2022 ₹21,763 Cr ▲ +13.6% ₹2,517 Cr 11.6% ₹31.17 ₹5.00
FY 2021 ₹19,160 Cr ▲ +11.8% ₹2,405 Cr 12.6% ₹29.79 ₹5.00
FY 2020 ₹17,132 Cr — ₹1,547 Cr 9.0% ₹19.16 ₹3.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
19%
81%
  • Total assets₹42,496 Cr
  • Total liabilities₹8,064 Cr
  • Shareholders' equity₹34,432 Cr
  • Total debt₹614 Cr
  • Cash & investments₹10,028 Cr
  • Current ratio3.44×
  • Revenue growth, 5 yr8.01% a year
  • EPS growth, 5 yr10.01% a year
  • Operating margin (TTM)13.27%
  • Net margin (TTM)11.88%

Cash flow — FY26

Operating activities
▲ ₹3,940 Cr
Investing activities
▼ −₹2,326 Cr
Financing activities
▼ −₹1,234 Cr
Free cash flow
▲ ₹861 Cr
Net change in cash
▲ ₹473 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue17,131.9919,159.5921,763.3422,753.1225,774.0927,547.6228,162.59
Cost of revenue6,936.818,328.649,560.759,314.249,957.2210,159.9210,868.88
Gross profit10,195.1810,830.9512,202.5913,438.8815,816.8717,387.7017,293.71
Operating expenses15,091.1915,960.0518,430.6019,047.0320,714.9821,391.0323,724.07
Operating income2,040.803,199.543,332.743,706.095,059.116,156.594,438.52
Depreciation1,097.311,000.57987.831,017.83939.10993.381,082.60
Profit before tax2,178.183,290.063,493.274,038.355,701.906,820.815,223.63
Tax631.20888.76933.801,202.861,546.591,529.761,353.84
Net profit1,546.522,404.872,516.752,801.914,121.555,272.523,879.23
EPS (₹)19.1629.7931.1734.6951.0565.2448.00
Dividend per share (₹)3.005.005.008.5013.0013.0013.00

What Analysts Say

36 analysts

Recommendations from 36 analysts who cover Cipla.

Buy average rating 2.31 on a 1–5 scale

▲ 22 bullish (61.1%) · 10 hold (27.8%) · ▼ 4 bearish (11.1%)

Votes

Strong Buy
8 (22%)
Buy
14 (39%)
Hold
10 (28%)
Sell
3 (8%)
Strong Sell
1 (3%)

How the votes changed

Rating3M ago2M ago1M ago1W agoNow3-month change
Strong Buy88888 —
Buy1414151414 —
Hold911101010 ▲ +1
Sell43333 ▼ −1
Strong Sell21111 ▼ −1

Analyst ratings are opinions, not a guarantee of returns.

Cipla vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yieldRating
Cipla ₹1,405.60 ▲ +1.68% ₹1,13,359 Cr 35.11 3.24 14.47% 11.88% 0.94% This stock
Sun Pharmaceutical Industries ₹1,855.65 ▼ −0.50% ₹4,45,222 Cr 38.40 5.55 14.22% 19.12% 0.83% Moderately Bearish
Divi's Laboratories ₹9,645.00 ▲ +0.50% ₹2,56,044 Cr 73.32 11.48 16.87% 24.32% 0.41% Bullish
Torrent Pharmaceuticals ₹4,936.80 ▼ −0.87% ₹1,87,773 Cr 72.73 19.22 23.00% 15.29% 0.80% Bullish
Zydus Lifesciences ₹1,175.00 ▲ +0.47% ₹1,17,207 Cr 21.19 4.24 17.90% 18.51% 0.09% Bullish
Lupin ₹2,099.00 ▼ −0.05% ₹95,980 Cr 19.12 4.98 12.70% 19.16% 0.74% Bearish

Rating = the data provider's overall technical view of each peer. Company names link to their own pages.

Shareholding Pattern

Who owns Cipla shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
29.2%
20.2%
20.6%
30.0%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter29.21%29.21%29.21%29.21% 0.00 pts
FII24.54%23.93%22.55%20.20% ▼ −2.35 pts
MF20.23%19.21%18.66%20.56% ▲ +1.90 pts
Other26.02%27.65%29.58%30.03% ▲ +0.45 pts

Cipla Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

CiplaBenchmarkComfortable → stretched

Valuation Is the price reasonable?

P/E (TTM)Price ÷ yearly earnings per share
35.11
▼ 4% below the sector average of 36.50
P/E, 12-month rangeLow 22.06 · high 35.14
100%
Today's P/E sits 100% of the way from its low to its high
P/BPrice ÷ book value per share
3.24
P/SPrice ÷ sales per share
3.94
P/CFPrice ÷ cash flow per share
24.83
PEGP/E ÷ earnings growth (≈1 is fair)
2.90

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
64.53%
▲ above its 5-yr average of 60.43%
Operating marginKept after running costs
13.27%
▼ below its 5-yr average of 18.01%
Pre-tax marginKept before tax
16.01%
▼ below its 5-yr average of 20.06%
Net marginKept as profit
11.88%
▼ below its 5-yr average of 14.85%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
11.82%
▼ below its 5-yr average of 14.47%
Return on assetsProfit on everything it owns
9.69%
▼ below its 5-yr average of 11.66%
Return on investmentProfit on long-term capital
11.52%
▼ below its 5-yr average of 14.07%

Growth Is the business getting bigger?

Revenue — last 12 months
+1.9%
▲ growing
Revenue — 3 yr, a year
+7.4%
▲ growing
Revenue — 5 yr, a year
+8.0%
▲ growing
EPS — last 12 months
−37.5%
▼ shrinking (off the scale)
EPS — 3 yr, a year
+11.4%
▲ growing
EPS — 5 yr, a year
+10.0%
▲ growing
Dividend — 3 yr, a year
+15.2%
▲ growing
Book value — 5 yr, a year
+13.4%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.02×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
3.44×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
2.48×
✓ Comfortable
Interest coverOperating profit ÷ interest to pay
71.06×
✓ Strong
Payout ratioShare of profit paid as dividend
27.07%
• Keeps most

Per share What each share stands for

EPS (TTM)
₹41.70
Book value
₹426.24
Cash flow
₹55.66
Dividend
₹13.00
Revenue
₹350.44

The share price is 3.30× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 109 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year28.82
Current Dividend Yield - Common Stock Primary Issue, LTM0.94
Price to Book - most recent fiscal year3.24
P/E Basic excluding extraordinary items - TTM35.11
P/E including extraordinary items - TTM33.16
P/E excluding extraordinary items low, trailing 12 months22.06
Price to Tangible Book - most fiscal year4.05
Dividend Yield - 5 Year Average0.86
Price to sales - most recent fiscal year3.97
Dividend Yield - indicated annual dividend divided by closing price0.94
Price to Cash Flow per share - trailing 12 month24.83
Peg Ratio2.90
P/E Normalized, most recent fiscal year26.88
P/E excluding extraordinary items high, trailing 12 months35.14
P/E excluding extraordinary items, most recent fiscal year quarter33.16
Price to sales - trailing 12 month3.94
Net Debt, LFY−94,143.50

Per share

Dividend Per Share - 5 year average10.50
Cash Flow per share - trailing 12 month55.66
Cash Flow per share - most recent fiscal year61.27
EPS including extraordinary items - trailing 12 month41.70
EPS including extraordinary items - most recent fiscal year48.00
EBITD per share - trailing 12 month64.47
Revenue/share - trailing 12 month350.44
EPS excluding extraordinary items - trailing 12 month41.70
EPS Basic excluding extraordinary items - most recent fiscal year48.03
EPS Basic excluding extraordinary items - trailing 12 month41.74
Book value per share - most recent fiscal year426.25
Dividend per share - most recent fiscal year13.00
Revenue/share - most recent fiscal year348.44
EPS Normalized - most recent fiscal year51.46
Book value (tangible) per share - most recent fiscal year341.45
Dividends per share - trailing 12 month13.00
EPS excluding extraordinary items - most recent fiscal year48.00
Cash per share - most recent fiscal year124.14

Margins

Operating margin - trailing 12 month13.27
Gross Margin - 5 year average60.43
Operating margin - 1st historical fiscal year15.76
Operating Margin - 5 year average18.01
Net Profit Margin % - 1st historical fiscal year13.74
Gross Margin - 1st historical fiscal year61.41
Net Profit Margin % - trailing 12 month11.88
Net Profit Margin - 5 year average14.85
Pretax Margin - 5 year average20.06
Pretax margin - 1st historical fiscal year18.55
Pretax margin - trailing 12 month16.01
Free Operating Cash Flow/Revenue, 5 Year Average6.31
Gross Margin - trailing 12 month64.53

Growth

EPS Change %, TTM over TTM−37.50
Revenue growth rate, 5 year8.01
EPS growth rate, 5 year10.01
Revenue Change % - most recent quarter 1 year ago2.33
Growth rate% - dividend, 3 year15.21
Growth rate% - EPS, 3 year11.43
Revenue/share (5 yr growth)7.98
Tangible Book Value, Total Equity, 5 Year CAGR15.38
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR2.75
Capital Spending growth rate, 5 year30.33
Revenue Change %, TTM over TTM1.85
Growth rate% - Revenue, 3 year7.37
Book value per share growth rate, 5 year13.41
EPS Change % - most recent quarter 1 year ago−39.23
Net Profit Margin growth rate, 5 year1.86
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR6.81
Total Debt, 5 Year CAGR−21.16

Financial strength

Free Cash Flow - most recent fiscal year−4,316.90
LT debt/equity - most recent fiscal year0.01
Quick ratio - most recent fiscal year2.48
Payout ratio - trailing 12 month31.15
Current ratio - most recent fiscal year3.44
Current EV/Free Cash Flow, LFY176.35
Total debt/total equity - most recent fiscal year0.02
Net Interest coverage - trailing 12 month71.06
Payout ratio - most recent fiscal year27.07

Returns & efficiency

Return on average equity - 5 year average14.47
Net Income/employee - trailing 12 month10,72,664.00
Revenue/employee - most recent fiscal year91,31,542.00
Return on investment - most recent fiscal year11.52
Return on average assets - most recent fiscal year9.69
Receivables turnover - most recent fiscal year5.03
Inventory turnover - most recent fiscal year1.72
Revenue/employee - trailing 12 month90,29,424.00
Return on average assets - 5 year average11.66
Net Income/employee - most recent fiscal year12,54,755.00
Asset turnover - most recent fiscal year0.71
Return on average equity - most recent fiscal year11.82
Return on investment - 5 year average14.07

Price & volume

Market Cap1,13,827.25
52 week Low Date2 Apr 2026
Price - 1 Day % Change−0.08
Relative (S&P500) price percent change - 13 week−1.04
Avg trading volume last 10 days0.99
Price - 13 week price percent change−3.82
Price - 52 week price percent change−9.44
Avg Trading Volume Last 3 months23.10
Price - 5 Day % Change1.84
Price % Change Month To Date−1.86
Relative (S&P500) price percent change - 04 week2.08
52 week High Date23 Oct 2025
Price - 26 week price percent change11.14
PDATE23 Sep 2026
Price - YTD price percent change−8.49
Relative (S&P500) price percent change - 52 week−0.63
NPRICE1,383.00
Relative (S&P500) price percent change - 26 week11.80
52 week Low1,165.70
52 week High1,673.00
Beta0.66
Relative (S&P500) price percent change - Year to Date4.22

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹13.00
₹13.00
  • Dividend yield0.94%
  • Payout ratio27.07%
  • 5-year average dividend₹10.50 a share
  • Latest dividend₹13.00 per share · 5 Jun 2026

Corporate calendar

  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹13.00 per share · 650% · Final dividend
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results
  • BoardQuarterly Results
Show 13 older events
  • MeetingAnnual General Meeting
  • Dividend₹13.00 per share · 650% · Final dividend
  • Dividend₹3.00 per share · 150% · Special special dividend
  • BoardAudited Results & Final Dividend
  • BoardQuarterly Results
  • BoardQuarterly Results
  • MeetingPostal Ballot
  • MeetingAnnual General Meeting
  • Dividend₹13.00 per share · 650% · Final dividend
  • MeetingAnnual General Meeting
  • Dividend₹8.50 per share · 425% · Final dividend
  • Dividend₹5.00 per share · 250% · Final dividend
  • Dividend₹5.00 per share · 250% · Final dividend

About Cipla

Biotechnology & Drugs

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.

Key people

  • Achin GuptaGlobal Chief Executive Officer, Managing Director, Executive Director
  • Ashish AdukiaGlobal Chief Financial Officer
  • Rajendra Kumar ChopraCompliance Officer, Company Secretary

Company facts

  • NSE symbolCIPLA
  • BSE code500087
  • ISININE059A01026
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 50, NIFTY 500
  • Market cap₹1,13,359 Cr
  • Revenue (FY26)₹28,163 Cr
  • Net profit (FY26)₹3,879 Cr

In the News

Recent headlines about Cipla — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →

Frequently Asked Questions

Cipla (NSE: CIPLA) last traded at ₹1,405.60 on the NSE, up 1.68% (₹23.22) on the day, as of 24 Sep 2026, 8:12 AM. On the BSE it was ₹1,403.20. The day's range was ₹1,367.00 – ₹1,418.70.

Cipla's 52-week high is ₹1,672.20 (23 Oct 2025) and its 52-week low is ₹1,165.55 (2 Apr 2026). At ₹1,405.60 the share is 15.9% below its high and 20.6% above its low.

Cipla's market capitalisation is ₹1,13,359 Cr (₹1.13L Cr). It is part of the NIFTY 50 index.

Cipla's P/E ratio (trailing 12 months) is 35.11. The sector average is 36.50, so investors pay 4% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹41.70.

Cipla shares are down 9.44% over the last year, down 8.49% so far this year, up 11.14% over 6 months, down 3.82% over 3 months. Over the last year the stock did 0.63% worse than the market.

In FY26 (year to Mar 2026), Cipla reported revenue of ₹28,163 Cr (up 2.23% on the year before) and a net profit of ₹3,879 Cr. Earnings per share were ₹48.00.

Yes. Cipla's latest dividend is ₹13.00 per share (650%, final dividend), with an ex-date of 5 Jun 2026. The dividend yield is 0.94%. It has paid 7 dividends in the records shown on this page.

Of 36 analysts covering Cipla, 22 are bullish (8 strong buy, 14 buy), 10 say hold and 4 are bearish. The consensus is Buy (average rating 2.31 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.

As of Jun 2026: Promoter 29.21%, FII 20.20%, MF 20.56%, Other 30.03%.

Cipla's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Lupin. By market capitalisation it ranks #5 of 6 in this group.